TCX-101 / Tacalyx - LARVOL DELTA

Two novel antibodies targeting different tumor-associated carbohydrate (TACA) antigens for the treatment of solid tumors show promising preclinical activity using different modes of action (AACR 2025) - "We focus on the generation of antibodies against these specific and difficult antigens and were able to obtain two high-affinity monoclonal antibodies (mAbs), TCX-101 and TCX-201, against two distinct TACA structures that are highly expressed across a broad range of cancer indications. In vitro studies show effective killing of various pancreatic (e.g. high expressing HuP-T4 cells with an IC50 for MMAE payload of 0.3 nM) and colon cancer cell lines expressing different levels of the target (e.g. Colo-205 (high expressing) with an IC50 of 0.013 nM or LS180 (medium expressing) with an IC50 of 4.7 nM), and high efficacy for both payloads in a xenograft mouse model using HuP-T4 pancreatic cancer cells. In conclusion, our antibodies against TACAs represent new promising treatment options for different cancer indications and can be effectively employed with different modes of action, depending on the target characteristics."

Preclinical • Colon Cancer • Colorectal Cancer • Lung Cancer • Oncology • Pancreatic Cancer • Small Cell Lung Cancer • Solid Tumor

Implementation and Validation of an Innovative Platform to Discover Monoclonal Antibodies Targeting Tumor-Associated Carbohydrate Antigens (TACAs) for Cancer Immunotherapy (EORTC-NCI-AACR 2024) - "TCX-101 led to a mAb with unmatched target affinity, and its humanized variant has similar activity to the parental one...The other project, TCX-201 also led to a mAb with superior target affinity compared to previously existing mAbs taken as reference and was used to define that the target is broadly expressed in pancreatic and colon cancers at high levels, as assessed by IHC.The platforms established at Tacalyx enable the generation of specific, high affinity mAbs, validated by the two projects that are currently in the preclinical stage. Further projects targeting novel and promising antigens have been initiated to broadly exploit these platforms, addressing currently unmet needs in cancer treatment."

IO biomarker • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor

Exploring the potential of TCX-101, an antibody targeting a tumor-associated carbohydrate antigen, as a bispecific T cell engager for the treatment of solid tumors (EORTC-NCI-AACR 2024) - "The investigation of breast cancer MDA-MB-231 cells, which have a very low TACA expression (EC50 of cell binding approx. 16µg/mL) and have been shown to be resistant to the ADC formats of TCX-101, showed sensitivity against the TcE indicated by T cell activation and partial tumor cell killing at concentrations >10µg/mL.In Conclusion, TACA-targeting TCX-101 as a TcE is a promising approach for the treatment of solid tumors."

Breast Cancer • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Generation of a novel antibody-drug conjugate, TCX-101, targeting a tumor-associated carbohydrate antigen (CIMT 2024) - "Tumor-growth inhibition was also observed in a CDX mouse model of NCI-H526 cells treated with the humanized TCX-101, while in vivo studies with mice bearing HCC-1428 cells are currently ongoing. The presented data places TCX-101 as a promising option for the treatment of various solid tumors that express the targeted TACA."

Breast Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • Lung Cancer • Melanoma • Oncology • Solid Tumor

Generation of a novel antibody-drug conjugate, TCX-101, targeting a tumor-associated carbohydrate antigen (CIMT 2024) - "Tumor-growth inhibition was also observed in a CDX mouse model of NCI-H526 cells treated with the humanized TCX-101, while in vivo studies with mice bearing HCC-1428 cells are currently ongoing. The presented data places TCX-101 as a promising option for the treatment of various solid tumors that express the targeted TACA."

Breast Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • Lung Cancer • Melanoma • Oncology • Solid Tumor

TCX-101, a novel antibody-drug conjugate targeting a tumor-associated carbohydrate antigen for the treatment of solid tumors (AACR 2024) - "A fully humanized version of TCX-101 with improved binding properties (EC50 6.27 nM vs. 8.13 nM) was generated and will be evaluated in further in vivo experiments. In conclusion, TCX-101 is a promising ADC for the treatment of various solid tumors."

Breast Cancer • Gastrointestinal Cancer • Melanoma • Oncology • Solid Tumor